<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Synaffix B.V. 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=35911></link><description><![CDATA[Synaffix B.V. 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Sat, 25 Apr 2026 14:54:42 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2020/09/12_3554238800_20200916172554_3203674800.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[Synaffix Wins Best Platform Technology at 7th Annual World ADC Awards]]></title><link>https://www.newswire.co.kr/newsRead.php?no=911635</link><description><![CDATA[AMSTERDAM--(Business Wire/Korea Newswire)--Synaffix B.V., a biotechnology company enabling antibody-drug conjugates (ADCs) with best-in-class therapeutic index, announces that it has won the “Best ADC Platform Technology” category at the 2020 World ADC Awards  ceremony.  Synaffix’ ADC platform consists of GlycoConnect™, HydraSpace™ and toxSYN™ which comprise site-specific technology and ...]]></description><pubDate>Mon, 05 Oct 2020 18:10:00 +0900</pubDate></item><item><title><![CDATA[시나픽스, ‘World ADC Awards 2020’ 서 최우수 ADC 플랫폼 기술상 부분 영예의 1등 수상]]></title><link>https://www.newswire.co.kr/newsRead.php?no=911636</link><description><![CDATA[암스테르담--(Business Wire/뉴스와이어)--네덜란드 기반 항체-약물 복합체(antibody-drug conjugates, ADC) 개발전문 바이오 기업 시나픽스(Synaffix B.V.)가 자사의 ADC 플랫폼 기술이 ‘2020년 세계 ADC 어워즈(World ADC Awards, )’ 행사에서 ‘최우수 ADC 플랫폼 기술(Best ADC Platform Technology)’ 부문의 영예의 1등에 선정되었다고 발표했다.   시나픽스의 ADC 플랫폼 기술은 글리코커넥트(GlycoConnect™)와 ...]]></description><pubDate>Mon, 05 Oct 2020 18:10:00 +0900</pubDate></item><item><title><![CDATA[Synaffix Sees Competitive Early In Vivo Data from ADCs Based on Proprietary Exatecan Linker-Payload]]></title><link>https://www.newswire.co.kr/newsRead.php?no=910783</link><description><![CDATA[AMSTERDAM--(Business Wire/Korea Newswire)--Synaffix B.V., a biotechnology company enabling antibody-drug conjugates (ADCs) with best-in-class therapeutic index, based on proprietary GlycoConnect™, HydraSpace™ and toxSYN™ technology platforms, announces promising findings from its latest in vivo benchmarking study.  In this mouse BT-474 xenograft study, trastuzumab-based ADCs prepared usi...]]></description><pubDate>Wed, 16 Sep 2020 17:31:35 +0900</pubDate></item></channel></rss>